Eosinophilic esophagitis
Conditions
Interventions
EoE patients will undergo two gastroscopies with allergen provocation tests. In one gastroscopy patients undergo esophageal allergen injections as described in our pilot study (NL54305.018.15 / METC 2
Sponsors
Amsterdam UMC, Location AMC
Eligibility
Inclusion criteria
Inclusion criteria: - Previous diagnosis of active EoE confirmed by histopathology e.g. presence of >15 eosinophilic granulocytes per high power field (hpf) in mid or proximal esophageal biopsies - Written informed consent - Age 18 – 75 years
Exclusion criteria
Exclusion criteria: - Inability to stop topical corticosteroids - Inability to stop beta-blockers and ACE inhibitors - Use of oral or systemic antihistaminics, oral cromoglicates, systemic corticosteroids, leukotriene inhibitors, or monoclonal antibodies, in the month preceding the study - Proven gastroesophageal reflux disease or other cause for esophageal eosinophilia - History of peptic ulcer disease - History of Barrett’s esophagus - History of GI cancer - ASA class III, IV or V - History of anaphylaxis - History of a severe systemic reaction to previous allergy tests (grade 3 or 4)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visible response to allergen provocation in the esophagus, defined as early phase response | — |
Secondary
| Measure | Time frame |
|---|---|
| - Immune response after allergen injection and flush of allergens, defined as activated immune cells observed in biopsies - Immune response to added allergens of esophageal mucosa in culture medium, defined as release of cytokines - Esophageal motility changes after allergen exposure | — |
Contacts
Public ContactLaura Haasnoot
Amsterdam UMC, location AMC
Outcome results
None listed